Journal article · 2026

Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis

Jonathan Barratt, Robert M. Brenner, Sean J. Barbour, Kirk Nicholas Campbell, Tom Doan, Necmi Eren, Jürgen Floege, Marshall W. Fordyce, Vivekanand Jha, Zeeshan Khawaja, Beom Seok Kim, Adrian Liew and 12 more

New England Journal of Medicine · Published 22 October 2026 · DOI 10.1056/nejmoa2610103

View at the publisherCite this paper

In brief

“Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis” is a 2026 journal article by Jonathan Barratt and 23 co-authors, published in New England Journal of Medicine. OpenAlex counts 2 citations as of 16 November 2026, which puts it in the top 5% of works published in 2026 by citations. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
2
Most cited in
2026 (2)
Field-weighted impact
7.81
References
25
Authors
24

Abstract

BackgroundAtacicept resulted in a significantly greater reduction in the urinary protein-to-creatinine ratio than placebo in a previously published analysis of this trial, ORIGIN 3. Final prespecified efficacy results are reported here. MethodsWe randomly assigned adults with biopsy-confirmed IgA nephropathy to receive weekly subcutaneous atacicept at a dose of 150 mg or placebo. We carried out… Read the full abstract at the publisher.

Excerpt. This paper is not open access.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Barratt, J., Brenner, R. M., Barbour, S. J., Campbell, K. N., Doan, T., Eren, N., Floege, J., Fordyce, M. W., Jha, V., Khawaja, Z., Kim, B. S., Liew, A., Maes, B., Pal, A., Pecoits‐Filho, R., Phoon, R. K. S., Rizk, D. V., Suzuki, H., Tesař, V., . . . Lafayette, R. A. (2026). Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2610103

MLA 9

Barratt, Jonathan, et al. “Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis.” New England Journal of Medicine, 2026. https://doi.org/10.1056/nejmoa2610103.

Chicago

Barratt, Jonathan, Robert M. Brenner, Sean J. Barbour, Kirk Nicholas Campbell, Tom Doan, Necmi Eren, Jürgen Floege, et al. 2026. “Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis.” New England Journal of Medicine. https://doi.org/10.1056/nejmoa2610103.

Harvard

Barratt, J. et al. (2026) ‘Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis’, New England Journal of Medicine. doi:10.1056/nejmoa2610103.

IEEE

J. Barratt et al., “Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis,” New England Journal of Medicine, 2026, doi: 10.1056/nejmoa2610103.

BibTeX

@article{barratt2026atacicept,
  title     = {{Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis}},
  author    = {Barratt, Jonathan and Brenner, Robert M. and Barbour, Sean J. and Campbell, Kirk Nicholas and Doan, Tom and Eren, Necmi and Floege, Jürgen and Fordyce, Marshall W. and Jha, Vivekanand and Khawaja, Zeeshan and Kim, Beom Seok and Liew, Adrian and Maes, Bart and Pal, Atanu and Pecoits‐Filho, Roberto and Phoon, Richard K. S. and Rizk, Dana V. and Suzuki, Hitoshi and Tesař, Vladimír and Trimarchi, Hernán and Wei, Xuelian and Yu, Lixi and Zhang, Hong and Lafayette, Richard A.},
  journal   = {New England Journal of Medicine},
  year      = {2026},
  doi       = {10.1056/nejmoa2610103},
  url       = {https://doi.org/10.1056/nejmoa2610103}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies

  • atacicept
  • IgA nephropathy
  • estimated glomerular filtration rate
  • kidney disease progression
  • eGFR slope
  • urine protein-to-creatinine ratio
  • subcutaneous administration
  • C5a receptor

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Barratt, J., Brenner, R. M., Barbour, S. J., Campbell, K. N., Doan, T., Eren, N., Floege, J., Fordyce, M. W., Jha, V., Khawaja, Z., Kim, B. S., Liew, A., Maes, B., Pal, A., Pecoits‐Filho, R., Phoon, R. K. S., Rizk, D. V., Suzuki, H., Tesař, V., . . . Lafayette, R. A. (2026). Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2610103

How many times has this paper been cited?

2 times, according to OpenAlex on 16 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Jonathan Barratt, Robert M. Brenner, Sean J. Barbour, Kirk Nicholas Campbell, Tom Doan, Necmi Eren, Jürgen Floege, Marshall W. Fordyce, Vivekanand Jha, Zeeshan Khawaja, Beom Seok Kim, Adrian Liew and 12 more.

What is the DOI of this paper?

10.1056/nejmoa2610103, permanently at https://doi.org/10.1056/nejmoa2610103. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 16 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.